American Society of Hematology 2019 guidelines for immune thrombocytopenia.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000966
Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000360
ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000644
Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018029496
Genome editing of HBG1 and HBG2 to induce fetal hemoglobin.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000820
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000692
Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018025718
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000593
Emicizumab use in major orthopedic surgery.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000228
Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000476
A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000300
Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000717
Metabolomic and molecular insights into sickle cell disease and innovative therapies.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018030619
Baboon envelope LVs efficiently transduced human adult, fetal, and progenitor T cells and corrected SCID-X1 T-cell deficiency.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018027508
Identification of a tumor-specific allo-HLA-restricted γδTCR.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019032409
Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018024216
Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000380
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019032276
Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000722
Butyrogenic bacteria after acute graft-versus-host disease (GVHD) are associated with the development of steroid-refractory GVHD.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000362
Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000516
Transient and chronic childhood immune thrombocytopenia are distinctly affected by Fc-γ receptor polymorphisms.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000068
Using a machine learning algorithm to predict acute graft-versus-host disease following allogeneic transplantation.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000934
Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000640
Genome-wide promoter methylation of hairy cell leukemia.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018024059
IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018026591
Identification of recurrent noncoding mutations in B-cell lymphoma using capture Hi-C.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018026419
Platelets inhibit apoptotic lung epithelial cell death and protect mice against infection-induced lung injury.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018026286
Impact of acquired del(17p) in multiple myeloma.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018028530
Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance.
来源期刊:Blood advancesDOI:10.1182/BLOODADVANCES.2019000400
Blood disease-causing and -suppressing transcriptional enhancers: general principles and GATA2 mechanisms.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000378
Characterization of a cryptic IGH/CCND1 rearrangement in a case of mantle cell lymphoma with negative CCND1 FISH studies.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019031450
Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018026054
Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000655
Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A.
来源期刊:Blood advancesDOI:10.1182/BLOODADVANCES.2017007914
Imetelstat inhibits growth of megakaryocyte colony-forming units from patients with essential thrombocythemia.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000167
Generation and function of progenitor T cells from StemRegenin-1-expanded CD34+ human hematopoietic progenitor cells.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018026575
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019001068
High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000450
TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000374
Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019030858
End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000883
Large-scale in vitro production of red blood cells from human peripheral blood mononuclear cells.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000689
Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018028886
Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018019851
Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018026203
Height-corrected low bone density associates with severe outcomes in sickle cell disease: SCCRIP cohort study results.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018026047
Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000051
Immunoadsorption and autologous transplantation for life-threatening primary antiphospholipid syndrome.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2019000465
Childhood use of antimicrobials and risk of Hodgkin lymphoma: a Danish register-based cohort study.
来源期刊:Blood advancesDOI:10.1182/bloodadvances.2018029355